
Rein Therapeutics, Inc.
97
Recent developments highlight Rein Therapeutics' progress in clinical trials and regulatory designations for its lead candidate LTI-03 in idiopathic pulmonary fibrosis.
- Rein Therapeutics received FDA Fast Track designation for LTI-03 in IPF as of August 20, 2026, facilitating potential expedited development and review processes [N1].
- The company provided an enrollment update for its Phase 2 RENEW study of LTI-03 in idiopathic pulmonary fibrosis patients as of April 30, 2026 [N2].
- Rein Therapeutics obtained FDA clearance to resume its Phase 2 trial evaluating LTI-03 in IPF patients as of November 3, 2025 [N3].
- HC Wainwright & Co. initiated coverage of Rein Therapeutics with a buy recommendation as of September 22, 2025 [N4].
- The company rebranded from Aileron Therapeutics to Rein Therapeutics in January 2025, focusing on pulmonary and fibrosis therapies [N7][N8].
Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in therapies for pulmonary fibrosis, with a lead candidate LTI-03 targeting idiopathic pulmonary fibrosis (IPF). The company rebranded from Aileron Therapeutics in early 2025 to focus on pulmonary and fibrosis therapies. Rein has received FDA Fast Track designation for LTI-03 and is actively conducting a Phase 2 clinical trial named RENEW, with enrollment progressing and FDA clearance to resume the trial after a pause. The company is listed on the Nasdaq Capital Market under ticker RNTX and maintains a strong liquidity position as of the latest quarter. The board and executive team have significant experience in biotech and pharmaceutical sectors.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary fibrosis, notably LTI-03 for idiopathic pulmonary fibrosis (IPF). The company has received FDA Fast Track designation for LTI-03 and is conducting a Phase 2 clinical trial (RENEW) with ongoing enrollment. As of September 30, 2026, the company reported $36.785 million in current assets, including cash and short-term investments, against $5.598 million in current liabilities, yielding strong liquidity ratios. The company reported a net loss of $5.537 million for the quarter ended September 30, 2026. The board comprises experienced directors with expertise in biotechnology and finance. The company faces Nasdaq listing compliance risk due to a recent notice regarding minimum bid price requirements.
The company has advanced its lead candidate LTI-03 through early clinical development, receiving FDA Fast Track designation, which may enhance regulatory engagement and development timelines. The ongoing Phase 2 RENEW study enrollment and FDA clearance to resume the trial indicate progress in clinical development. Rein Therapeutics' focused pipeline in pulmonary fibrosis addresses a significant unmet medical need, supported by a management team with relevant industry experience. The company's strong liquidity position as of September 2026 provides operational runway for continued development.
Rein Therapeutics operates as a clinical-stage biopharmaceutical company with no approved products and ongoing clinical trials that carry inherent risks of failure or delay. The company reported a net loss and negative earnings per share for the latest quarter, reflecting ongoing development expenses without revenue generation. The Nasdaq notice regarding minimum bid price non-compliance introduces potential listing risks. The success of the company is contingent on clinical trial outcomes, regulatory approvals, and the ability to secure additional financing if needed.
Rein Therapeutics' moat is primarily based on its specialized focus on pulmonary fibrosis therapies and its lead drug candidate LTI-03, which has received FDA Fast Track designation, potentially facilitating expedited development and review. The company's clinical-stage status and ongoing Phase 2 trial represent a critical step in establishing clinical efficacy and safety. The expertise of its management and board in biotechnology and drug development supports its strategic execution. However, as a clinical-stage company without approved products, its moat depends heavily on successful clinical outcomes and regulatory approvals.
• Clinical Development Risk: The success of Rein Therapeutics depends on the outcomes of clinical trials for LTI-03, which may fail to demonstrate safety or efficacy.
• Regulatory Risk: Regulatory approvals are uncertain and delays or denials could adversely affect the company's development timeline and prospects.
• Financial Risk: The company reported net losses and relies on external financing; failure to secure sufficient capital could impair operations.
• Market Listing Risk: The company received a Nasdaq notice for non-compliance with minimum bid price requirements, risking potential delisting if compliance is not regained.
Business trends: Continued clinical development of LTI-03 for idiopathic pulmonary fibrosis with FDA Fast Track designation and active Phase 2 trial enrollment.
Execution milestones: Completion of Phase 2 RENEW study enrollment, regulatory interactions, and maintaining Nasdaq listing compliance.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, financial sustainability, and Nasdaq listing compliance risk.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on pulmonary and fibrosis therapies.
- The company is developing LTI-03, a drug candidate for idiopathic pulmonary fibrosis (IPF).
- Rein Therapeutics received FDA Fast Track designation for LTI-03 in IPF as of August 20, 2026.
- The company is conducting a Phase 2 clinical trial named RENEW for LTI-03 in IPF patients, with enrollment updates provided as of April 30, 2026.
- Rein Therapeutics obtained FDA clearance to resume the Phase 2 trial of LTI-03 in IPF patients as of November 3, 2025.
- The company rebranded from Aileron Therapeutics to Rein Therapeutics in January 2025, focusing on pulmonary and fibrosis therapies.
- As of September 30, 2026, Rein Therapeutics had cash and cash equivalents of $943,000 and short-term investments of $34.55 million, totaling $36.785 million in current assets against $5.598 million in current liabilities, resulting in a current ratio of 6.57 and a cash ratio of 6.34.
- The company reported a net loss of $5.537 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.06.
- The board of directors consists of experienced members with backgrounds in biotechnology, pharmaceutical development, and finance, including CEO Brian Windsor, Ph.D.
- The company is listed on the Nasdaq Capital Market under the ticker RNTX.
- The company received a Nasdaq notice in August 2026 for non-compliance with the minimum bid price requirement but has a compliance period until February 17, 2027.
- No material changes to risk factors were reported in the latest SEC filings beyond the Nasdaq listing compliance issue.
Generated 2026-11-16
- S1 | 2026-04-27 | 10-K/A
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-08-20 | www.nasdaq.com | Rein Therapeutics Receives FDA Fast Track Designation For LTI-03 In IPF | https://www.nasdaq.com/articles/rein-therapeutics-receives-fda-fast-track-designation-lti-03-ipf
- N2 | 2026-04-30 | www.nasdaq.com | Rein Provides Enrollment Update For Phase 2 RENEW Study Of LTI-03 In Idiopathic Pulmonary Fibrosis | https://www.nasdaq.com/articles/rein-provides-enrollment-update-phase-2-renew-study-lti-03-idiopathic-pulmonary-fibrosis
- N3 | 2025-11-03 | www.nasdaq.com | Rein Therapeutics Gets FDA Clearance To Resume Phase 2 Trial Evaluating LTI-03 In Patients With IPF | https://www.nasdaq.com/articles/rein-therapeutics-gets-fda-clearance-resume-phase-2-trial-evaluating-lti-03-patients-ipf
- N4 | 2025-09-22 | www.nasdaq.com | HC Wainwright & Co. Initiates Coverage of Rein Therapeutics (RNTX) with Buy Recommendation | https://www.nasdaq.com/articles/hc-wainwright-co-initiates-coverage-rein-therapeutics-rntx-buy-recommendation
- N5 | 2025-04-07 | www.nasdaq.com | $RNTX Earnings Results: $RNTX Reports Quarterly Earnings | https://www.nasdaq.com/articles/rntx-earnings-results-rntx-reports-quarterly-earnings
- N6 | 2025-04-05 | www.nasdaq.com | $RNTX Earnings Preview: Recent $RNTX Insider Trading, Hedge Fund Activity, and More | https://www.nasdaq.com/articles/rntx-earnings-preview-recent-rntx-insider-trading-hedge-fund-activity-and-more
- N7 | 2025-01-10 | www.nasdaq.com | Aileron Therapeutics Rebrands As Rein Therapeutics | https://www.nasdaq.com/articles/aileron-therapeutics-rebrands-rein-therapeutics
- N8 | 2025-01-10 | www.nasdaq.com | Rein Therapeutics Rebrands And Focuses On Pulmonary And Fibrosis Therapies | https://www.nasdaq.com/articles/rein-therapeutics-rebrands-and-focuses-pulmonary-and-fibrosis-therapies
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


